Compare SKLZ & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKLZ | IFRX |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.0M | 86.0M |
| IPO Year | N/A | 2017 |
| Metric | SKLZ | IFRX |
|---|---|---|
| Price | $5.73 | $1.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $8.50 |
| AVG Volume (30 Days) | 53.0K | ★ 6.5M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,256,000.00 | $73,729.00 |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $12.68 | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.54 | $0.71 |
| 52 Week High | $9.11 | $2.77 |
| Indicator | SKLZ | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 42.82 |
| Support Level | $5.27 | $1.04 |
| Resistance Level | $5.87 | $1.12 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 80.99 | 38.45 |
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.